{"abstract":"This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in U.S. Provisional Patent Application No. 60/844,027 entitled, \"Azonafide derived tumor and cancer targeting compounds,\" filed September 12, 2006 [HHS Ref. No. E- 160-2006/0-US-01], PCT Application No. PCT/US2007/078233 entitled, \"Azonafide derived tumor and cancer targeting compounds,\" filed September 12, 2007 [HHS Ref. No. E-160-2006/0-PCT-02], European Patent Application No. 7842310.0 entitled, \"Azonafide derived tumor and cancer targeting compounds,\" filed September 12, 2007 [HHS Ref. No. E- 160-2006/0-EP-03], and U.S. Patent Application No. 12/441,029 entitled, \"Azonafide derived tumor and cancer targeting compounds,\" filed March 12, 2009 now US Patent No. 8,008,316 issued August 30, 2011 [HHS Ref. No. E-160-2006/0-US-04], and all related continuing and foreign patents/patent applications for the technology family, to Oncolinx, Inc. The patent rights in these inventions have been assigned to the Government of the United States of America. The prospective exclusive evaluation option license territory may be worldwide and the field of use may be limited to the development and use of the licensed patent rights as a component of an antibody-drug conjugate for the treatment of human cancers. Upon expiration or termination of the exclusive evaluation option license, Oncolinx will have the right to execute an exclusive patent commercialization license which will supersede and replace the exclusive evaluation option license with no broader territory than granted in the exclusive evaluation option license and the field of use will be commensurate with the commercial development plan at the time of conversion.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2014/09/15/2014-21855.html","cfr_references":[],"citation":"79 FR 54987","comment_url":null,"comments_close_on":"2014-09-30","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 30, 2014 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2014-21855","effective_on":null,"end_page":54987,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2014/09/15/2014-21855.xml","html_url":"https://www.federalregister.gov/documents/2014/09/15/2014-21855/prospective-grant-of-exclusive-evaluation-license-development-of-antibody-drug-conjugates-comprising","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2014-21855?publication_date=2014-09-15","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2014-09-15/2014-21855/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":107,"last_updated":"2026-07-28 08:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2014-09-15/pdf/2014-21855.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2014-21855.pdf?1410525981","publication_date":"2014-09-15","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2014/09/15/2014-21855.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=NIH_FRDOC_0001","supporting_documents_count":0,"docket_id":"NIH_FRDOC_0001","regulation_id_number":null,"title":"Recently Posted NIH Rules and Notices.","checked_regulationsdotgov_at":"2014-10-05T06:00:17Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":54987,"subtype":null,"title":"Prospective Grant of Exclusive Evaluation License: Development of Antibody-Drug Conjugates Comprising Topoisomerase Inhibitors for the Treatment of Human Cancers","toc_doc":"Antibody-Drug Conjugates Comprising Topoisomerase Inhibitors for the Treatment of Human Cancers","toc_subject":"Exclusive Licenses:","topics":[],"type":"Notice","volume":79}